Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2008-09-05
2009-10-13
Bernhardt, Emily (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C514S253070
Reexamination Certificate
active
07601837
ABSTRACT:
The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
REFERENCES:
patent: 5576338 (1996-11-01), Friesen et al.
patent: 5596001 (1997-01-01), Hamanaka
patent: 6172084 (2001-01-01), Cuny et al.
patent: 6187805 (2001-02-01), Pineiro et al.
patent: 6207679 (2001-03-01), Cuny et al.
patent: 6310212 (2001-10-01), Yuan et al.
patent: 6316450 (2001-11-01), Bromidge et al.
patent: 6376670 (2002-04-01), Cuny et al.
patent: 6380199 (2002-04-01), Reavill et al.
patent: 6403808 (2002-06-01), Glennon et al.
patent: 6489488 (2002-12-01), Glennon et al.
patent: 6518297 (2003-02-01), Glennon et al.
patent: 6548504 (2003-04-01), Bromidge et al.
patent: 6787535 (2004-09-01), Beard et al.
patent: 6849644 (2005-02-01), Bromidge et al.
patent: 7084169 (2006-08-01), Zhao
patent: 7087750 (2006-08-01), Caldirola et al.
patent: 7098233 (2006-08-01), Di Cesare et al.
patent: 7262188 (2007-08-01), MacDonald et al.
patent: 7452888 (2008-11-01), Ahmed et al.
patent: 2001/0051719 (2001-12-01), Bromidge et al.
patent: 2003/0144505 (2003-07-01), Bromidge et al.
patent: 2004/0024210 (2004-02-01), Johansson et al.
patent: 2004/0034036 (2004-02-01), Bromidge et al.
patent: 2004/0132742 (2004-07-01), Bromidge et al.
patent: 2004/0167030 (2004-08-01), Bernotas et al.
patent: 2005/0090485 (2005-04-01), Bromidge et al.
patent: 2005/0090496 (2005-04-01), Ahmed et al.
patent: 2005/0176705 (2005-08-01), Bromidge
patent: 2005/0176759 (2005-08-01), Ahmed et al.
patent: 2006/0287334 (2006-12-01), Johnson et al.
patent: 2007/0027139 (2007-02-01), Johnson et al.
patent: 2007/0032504 (2007-02-01), Gladwin
patent: 2007/0191345 (2007-08-01), Ahmed et al.
patent: 2007/0249603 (2007-10-01), Johnson et al.
patent: 2007/0275979 (2007-11-01), Macdonald et al.
patent: 2169231 (1996-08-01), None
patent: 0 605 981 (1996-02-01), None
patent: 0 818 449 (1998-01-01), None
patent: 0 631 176 (2000-12-01), None
patent: 0 867 477 (2002-05-01), None
patent: 2341549 (2000-03-01), None
patent: 02262627 (1990-10-01), None
patent: WO 95/11592 (1995-05-01), None
patent: WO 97/32858 (1997-09-01), None
patent: WO 98/27081 (1998-06-01), None
patent: WO 98/47874 (1998-10-01), None
patent: WO 98/54157 (1998-12-01), None
patent: WO 98/54158 (1998-12-01), None
patent: WO 98/57931 (1998-12-01), None
patent: WO 98/57952 (1998-12-01), None
patent: WO 99/42465 (1999-08-01), None
patent: WO 99/47516 (1999-09-01), None
patent: WO 99/65906 (1999-12-01), None
patent: WO 99/65906 (1999-12-01), None
patent: WO 00/12073 (2000-03-01), None
patent: WO 00/13681 (2000-03-01), None
patent: WO 00/34265 (2000-06-01), None
patent: WO 00/42026 (2000-07-01), None
patent: WO 00/58303 (2000-10-01), None
patent: WO 00/58313 (2000-10-01), None
patent: WO 00/63203 (2000-10-01), None
patent: WO 00/63203 (2000-10-01), None
patent: WO 00/64877 (2000-11-01), None
patent: WO 01/16108 (2001-03-01), None
patent: WO0117963 (2001-03-01), None
patent: WO 01/32646 (2001-05-01), None
patent: WO 01/32660 (2001-05-01), None
patent: WO 01/40217 (2001-06-01), None
patent: WO0198279 (2001-12-01), None
patent: WO 02/08178 (2002-01-01), None
patent: WO 02/20489 (2002-03-01), None
patent: WO 02/28837 (2002-04-01), None
patent: WO 02/36562 (2002-05-01), None
patent: WO 02/44170 (2002-06-01), None
patent: WO 02/89811 (2002-11-01), None
patent: WO 02/098857 (2002-12-01), None
patent: WO 02/102774 (2002-12-01), None
patent: WO 03/011284 (2003-02-01), None
patent: WO 03/013510 (2003-02-01), None
patent: WO03014097 (2003-02-01), None
patent: WO 03020707 (2003-03-01), None
patent: WO 03/037872 (2003-05-01), None
patent: WO 03/066056 (2003-08-01), None
patent: WO 03/072558 (2003-09-01), None
patent: WO 03/080608 (2003-10-01), None
patent: WO03095434 (2003-11-01), None
patent: WO 2004/000828 (2003-12-01), None
patent: WO03104193 (2003-12-01), None
patent: WO2004026830 (2004-04-01), None
patent: WO2004026831 (2004-04-01), None
patent: WO2004035047 (2004-04-01), None
patent: WO2004041792 (2004-05-01), None
patent: WO 2004050085 (2004-06-01), None
patent: WO2004078176 (2004-09-01), None
patent: WO2004080969 (2004-09-01), None
patent: WO 2005/021530 (2005-03-01), None
patent: WO 2006/038006 (2006-04-01), None
patent: WO 2007/039219 (2007-04-01), None
patent: WO 2007/039220 (2007-04-01), None
patent: WO 2007/039238 (2007-04-01), None
Mitchell et al.,Pharmacol.& Therapeutics, 108: 320-333 (2005).
Chuang et al.,Alzheimer's & Dementia, The Journal of the Alzheimer's Association, 2(3/Supp. 1): S631-S632 (2006).
London Stock Exchange Announcement—GlaxoSmithKline (GSK) plc, Issued on Thursday, Dec. 13, 2007, New York, New York.
A Dose Ranging Study to Investigate the Efficacy and Safety of SB-742457 in Alzheimer's Disease. NCT ID No: NCT00224497 (Verified 2007).
SB-742457 and Donepezil in Alzheimer's Disease. NCT ID No: NCT00348192 (2006).
Garcia-Alloza et al.Neuropsychopharmacology, 29: 410-416 (2004).
Davies et al.,Drugs of the Future, 30(5): 479-495 (2005).
Boes et al.Eur. J. Med. Chem., 36(2): 165-178 (2001).
Hirst et al.Mol. Pharmacol., 64: 1295-1308 (2003).
Sleight et al.Br. J. Pharmacol., 124(3): 556-562 (1998).
Lindner et al.J. Pharmacol. Exp. Ther., 307(2): 682-691 (2003).
Riemer et al.J. Med. Chem., 46(7): 1273-1276 (2003).
Chang-Fong et al.Bioorg. Med. Chem. Lett., 14(8): 1961-1964 (2004).
Glennon et al.J. Med. Chem., 43(5): 1011-1018 (2000).
Russell et al.,J. Med. Chem., 44(23): 3881-3895 (2001).
Pineiro-Nunez et al.229thACS Natl. Mtg., Mar. 13-17, San Diego, Abst. Medi 282 (2005).
Stadler et al.37thIUPAC Cong. Aug. 14-19, Berlin, Abst MM-7 (1999).
Holenz et al.J. Med. Chem., 48(6): 1781-1795 (2005).
Ahmed et al.Bioorganic&Medicinal Chem. Letters., 15: 4867-4871 (2005).
Bourson et al.British Journal of Pharmacol., 125: 1562-1566 (1998).
Sleight et al.British Journal of Pharmacol., 124: 556-562 (1998).
Bentley et al.British Journal of Pharmacol., 126: 1537-1542 (1999).
Bentley et al.British Journal of Pharmacol., 126 (Suppl.): 66 (1999).
Thome et al.Journal of Neural Transmission, 108: 1175-1180 (2001).
Bentley et al.Journal of Psychopharmacology, A64 (Suppl.): 255 (1997).
Foley et al.Neuropsychopharmacology, 29: 93-100 (2004).
Tsai et al.Neuroscience Letters, 276: 138-139 (1999).
Kan et al.Neuroscience Letters, 372: 27-29 (2004).
Bourson et al.J. Pharmacol. &Exp. Therapeutics, 274: 173-180 (1995).
Robichaud et al.Annual Reports in Med. Chem., 36: 11-20 (2000).
Rogers et al.Psychopharmacology, 158: 114-119 (2001).
Bromidge et al.Bioorg. &Med. Chem. Lett., 11: 55-58 (2001).
Ahmed Mahmood
Johnson Christopher Norbert
MacDonald Gregor James
Moss Stephen Frederick
Thompson Mervyn
Bernhardt Emily
Glaxo Group Limited
Kinzig Charles M.
Sieburth Kathryn L.
LandOfFree
Quinoline derivatives and their use as 5-HT6 ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoline derivatives and their use as 5-HT6 ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline derivatives and their use as 5-HT6 ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4068950